Preclinical Characterization of Anti-SIRPα mAb BYON4228 Published in Journal for ImmunoTherapy of Cancer

/PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that the Journal for...

Related Keywords

Netherlands ,Nijmegen ,Gelderland ,Dutch ,Marco Timmers ,Yvonne Massar ,Wim Dokter ,Prnewswire Byondis ,Public Eyes Healthcare Communications ,Society For Immunotherapy Of Cancer ,Corporate Communications ,Byondi Lead ,Enter Phasei Study This ,Signal Regulatory Protein ,Chief Scientific Officer Wim Dokter ,Chief Executive Officer Marco Timmers ,Good Manufacturing Practice ,Public Eyes Healthcare ,Byondisbv ,